Xynomic to explore AI-enabled drugs with DIP



Sino-US biotech Xynomic Pharmaceuticals Holdings Inc., (Nasdaq.XYNO) was in talks with Beijing-based artificial intelligence (AI) firm Deep Intelligent Pharma (DIP) on January 13, concerning bolstering innovative research and development through AI-empowered small-molecule targeted anti-cancer drugs. An agreement reached will involve developing a kirsten rat sarcoma viral oncogene homolog (KRAS) mutant protein targeting molecule, screening selective anaplastic lymphoma kinase (ALK5) inhibitors, and developing a poly (ADP-ribose) polymerase (PARP) inhibitor targeting breast cancer susceptibility gene (BRCA)-deficient tumors.

Xynomic is developing the following 3 drugs:

Abexinostat, a histone deacetylase (HDAC) approved for trials in March 2019. It is under global key clinical studies in combination with pazopanib in renal cell carcinoma, and as a monotherapy for non-Hodgkins lymphoma (NHL).

ATP-competitive mTORC1/2 inhibitor XP-105 (BI 860585). Xynomic Pharma struck a USD 800 million licensing deal with Germany major Boehringer-Ingelheim (BI) in December 2018, taking global development, manufacturing and commercialization rights to the drug. XP-105 was proven to be effective in multiple solid tumors in a Phase I study, and is entering Phase II clinical trials.

Pan-RAF inhibitor XP-102 (BI 882370) was also licensed from BI, via a USD 502 million deal in November 2017, for global development, manufacturing and commercialization rights.


Reference:

Related news
Sino-US biotech Xynomic Pharmaceuticals Holdings Inc., (Nasdaq.XYNO) announced first China patient dosing in a Phase III clinical study for abexinostat as a first-line or second-line treatment of locally advanced or metastatic renal cell carcinoma (RCC) in combination with pazopanib. Abexinostat, a potent histone deacetylase (HDAC) inhibitor, delivered reliable efficacy and controllable toxicity in a Phase Ib clinical trial in combination with pazopanib.
Sino-U.S. biotech Xynomic Pharmaceuticals Holdings Inc., (Nasdaq.XYNO) announced the receipt of clinical trial approval from the National Medical Products Administration (NMPA) in China to start two pivotal-stage studies assessing its lead pipeline candidate abexinostat in treating lymphoma.
  • 1564723651803
  • China
  • Drug
Sino-U.S. biotech Xynomic Pharma announced the receipt of clinical trial approvals in China, Spain, and Poland for its histone deacetylase (HDAC) inhibitor abexinostat in combination with pazopanib for patients with renal cell carcinoma (RCC).
  • 1552879902162
  • China
  • Drug
Sino-U.S. biotech Xynomic Pharma announced the initiation of a Phase III clinical trial in South Korea for a combination pairing of the firm’s abexinostat with GlaxoSmithKline’s multi-kinase inhibitor Votrient (pazopanib) as a treatment for renal cell carcinoma (RCC).
  • 1551062654521
  • China
  • Drug
Sino-U.S. biotech Xynomic Pharma announced that it has made three investigational new drug (IND) filings with China’s National Medical Products Administration (NMPA) for its lead innovative pipeline candidate abexinostat.
Recent news
Beigene Ltd released a press release announcing its successful bid for Abraxane paclitaxel (nanoparticle ablumin-bound) during the recently completed second round of the volume-based procurement (VBP) program.
US major Eli Lilly’s type 2 diabetes drug candidate tirzepatide (LY3298176) has obtained 6 tacit clinical trial approvals from the Center for Drug Evaluation (CDE), according to the bureau’s website.
China-based biotech BeiGene Ltd (Nasdaq.BGNE) announced that a Phase III clinical study for the programmed death-1 (PD-1) antibody tislelizumab in combination with two chemotherapies reached primary endpoint in a Phase III study as a first-line treatment for squamous non-small cell lung cancer (sqNSCLC).
  • 1579661419502
  • China
  • Drug
Hangzhou-based Gmax Biopharm LLC picked up a tacit clinical trial approval for GMA301, a Class 1 recombinant anti-human endothelin receptor A monoclonal antibody (mAb).
Hutchison China MediTech Ltd (Chi-Med; AIM/Nasdaq:HCM) announced plans to offer USD 110 million of American Depositary Shares (ADSs) on the Nasdaq Global Select Market.
Some good news for Wuhan amid dark times.
Mexico’s Ministry of Health (SSA) has announced it will update its treatment protocols for the 15 most common types of cancer in the country, as well as diabetes and hypertension.
Analytics Snapshot


Analytics Snapshot